The experiment on AD transgenic mice proved that NGX267 represents an effective peripherally administered drug to attenuate the major hallmarks of AD and to reverse deficits in cognition, like the reduction of the Aβ and tau pathologies in the hippocampus and cortex. This evidence concerns the gene MAPT and Alzheimer disease.